Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options


#196711

N/A

GBI Research

$ 3500

In Stock

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Novel HER-2 Positive Therapies Provide Diversified Treatment Options’, which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

 

Scope

 

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.

 

The report includes:

 

  • Disease overview, as well as treatment algorithms and treatment usage patterns
  • Market size and forecast for the APAC breast cancer market from 2013 to 2020
  • Major marketed products in the APAC region along with a heat map of product performance
  • In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements that could have impact on growth trends

 

Reasons to Buy

 

The report will enhance your decision-making capability by allowing you to:

 

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table of Contents

 

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

 

2 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 -Introduction 9

2.1 Breast Cancer 9

2.2 Symptoms 9

2.3 Epidemiology 10

2.4 Pathophysiology 11

2.5 Diagnosis 11

2.6 Prognosis and Disease Staging 12

2.6.1 Classification 13

2.7 Treatment Options 14

2.7.1 Surgery and Radiation Therapy 14

2.7.2 Chemotherapy 14

2.7.3 Hormonal Therapies 15

2.7.4 Targeted Therapies 15

2.7.5 Resistance to Pharmacological Therapies 16

2.7.6 Treatment Guidelines 16

2.7.7 Measuring the Effectiveness of Treatment 18

 

3 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products 20

3.1 Key Marketed Products 20

3.1.1 Herceptin 20

3.1.2 Halaven 22

3.1.3 Avastin 22

3.1.4 Gemzar 23

3.1.5 Taxotere 24

3.1.6 Tykerb 25

3.1.7 Femara 26

3.1.8 Aromasin 26

3.1.9 Zoladex 26

3.1.10 Arimidex 27

3.2 Heat Map for Marketed Products 27

 

4 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Pipeline Analysis 29

4.1 Overall Pipeline 29

4.2 Pipeline Analysis by Molecule Type 31

4.3 Pipeline Analysis by Mechanism of Action 33

4.4 Clinical Trials - Failure Rate 35

4.5 Clinical Trial Size 36

4.6 Duration 38

4.7 Promising Drug Candidates in Pipeline 39

4.7.1 Buparlisib 39

4.7.2 Palbociclib 39

4.7.3 Afatinib dimaleate 39

4.7.4 Entinostat 40

4.7.5 Neratinib 40

4.7.6 BMN-673 41

4.7.7 Etirinotecan pegol 41

 

5 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Market Forecast to 2020 42

5.1 Asia-Pacific Market 42

5.1.1 Treatment Usage Patterns 42

5.1.2 Market Size 42

5.2 India 44

5.2.1 Treatment Usage Patterns 44

5.2.2 Annual Cost of Therapy 44

5.2.3 Market Size 44

5.3 Australia 46

5.3.1 Treatment Usage Patterns 46

5.3.2 Annual Cost of Therapy 46

5.3.3 Market Size 46

5.4 China 48

5.4.1 Treatment Usage Patterns 48

5.4.2 Annual Cost of Therapy 48

5.4.3 Market Size 48

5.5 Japan 50

5.5.1 Treatment Usage Patterns 50

5.5.2 Annual Cost of Therapy 50

5.5.3 Market Size 50

5.6 Drivers and Barriers for the Breast Cancer Therapeutics in Asia-Pacific Market to 2020 52

5.6.1 Drivers 52

5.6.2 Barriers 53

 

6 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Deals and Strategic Consolidations 54

6.1 Licensing Agreements 54

6.1.1 Major Licensing Deals 57

6.2 Co-development Agreements 58

6.2.1 Major Co-development Agreements 60

 

7 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Appendix 62

7.1 All Pipeline Drugs by Phase 62

7.1.1 Discovery 62

7.1.2 Preclinical 65

7.1.3 IND/CTA-Filed and Phase I 77

7.1.4 Phase II 83

7.1.5 Phase III 90

7.1.6 Pre-Registration 93

7.2 Market Forecasts to 2020 93

7.2.1 Asia-Pacific 93

7.2.2 India 93

7.2.3 Australia 94

7.2.4 China 94

7.2.5 Japan 94

7.3 Market Definitions 95

7.4 Abbreviations 95

7.5 References 97

7.6 Research Methodology 100

7.6.1 Coverage 100

7.6.2 Secondary Research 100

7.6.3 Primary Research 101

7.6.4 Therapeutic Landscape 101

7.6.5 Geographical Landscape 103

7.6.6 Pipeline Analysis 104

7.7 Expert Panel Validation 104

7.8 Contact Us 104

7.9 Disclaimer 104

Table 1: Market for Monoclonal Antibodies in Breast Cancer Therapeutics Market, Global, Tumor, Nodes and Metastasis Staging, 2010–2013 12

Table 2: Market for Monoclonal Antibodies in Breast Cancer Therapeutics Market, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013 13

Table 3: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 62

Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013 65

Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed and Phase I), 2013 77

Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 83

Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013 90

Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Pre-Registration), 2013 93

Table 9: Market for Breast Cancer Therapeutics, Asia-Pacific, Forecast Data, 2013–2020 93

Table 10: Market for Breast Cancer Therapeutics, India, Forecast Data, 2013–2020 93

Table 11: Market for Breast Cancer Therapeutics, Australia, Forecast Data, 2013–2020 94

Table 12: Market for Breast Cancer Therapeutics, China, Forecast Data, 2013–2020 94

Table 13: Market for Breast Cancer Therapeutics, Japan, Forecast Data, 2013–2020 94

Figure 1: Breast Cancer Therapeutics Market, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2013 17

Figure 2: Breast Cancer Therapeutics Market, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2013 18

Figure 3: Breast Cancer Therapeutics Market, Global, Heat Map (Marketed Products) 28

Figure 4: Breast Cancer Therapeutics Market, Global, Pipeline by Stage of Development and Program Type, 2013 30

Figure 5: Breast Cancer Therapeutics Market, Global, Pipeline by Molecule Type and Stage of Development, 2013 32

Figure 6: Breast Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action and Stage of Development, 2013 34

Figure 7: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rate (%), 2013 35

Figure 8: Breast Cancer Therapeutics Market, Global, Clinical Trial Size (Participants), 2013 37

Figure 9: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration (months), 2013 38

Figure 10: Breast Cancer Therapeutics Market, Market Size ($m), 2013–2020 43

Figure 11: Breast Cancer Therapeutics Market, India, Market Size ($m), 2013–2020 45

Figure 12: Breast Cancer Therapeutics Market, Australia, Market Size ($m), 2013–2020 47

Figure 13: Breast Cancer Therapeutics Market, China, Market Size ($m), 2013–2020 49

Figure 14: Breast Cancer Therapeutics Market, Japan, Market Size ($m), 2013–2020 51

Figure 15: Breast Cancer Therapeutics Market, Global, Licensing Agreements, 2006–2013 54

Figure 16: Breast Cancer Therapeutics in APAC Market to 2020, Global, Licensing Agreements, 2006-2013 55

Figure 17: Breast Cancer Therapeutics in APAC Market to 2019, Global, Licensing Agreements, 2006-2013 56

Figure 18: Breast Cancer Therapeutics APAC Market to 2019, Global, Co-Development Deals, 2006-2013 58

Figure 19: Breast Cancer in APAC Market to 2019, Global, Co-Development Agreements, 2006-2013 59

Figure 20: GBI Research Market Forecasting Model 103